Brokerages forecast that Radius Health Inc (NASDAQ:RDUS) will post ($1.49) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Radius Health’s earnings, with the highest EPS estimate coming in at ($1.42) and the lowest estimate coming in at ($1.56). Radius Health reported earnings of ($1.22) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 22.1%. The business is expected to report its next quarterly earnings report on Thursday, February 22nd.
On average, analysts expect that Radius Health will report full year earnings of ($5.62) per share for the current fiscal year, with EPS estimates ranging from ($5.77) to ($5.30). For the next year, analysts anticipate that the firm will post earnings of ($5.05) per share, with EPS estimates ranging from ($5.98) to ($3.91). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Radius Health.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the business posted ($1.07) earnings per share.
Radius Health (RDUS) opened at $38.02 on Friday. The firm has a market cap of $1,610.66, a P/E ratio of -7.00 and a beta of 1.10. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16.
In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the transaction, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the transaction, the insider now directly owns 5,698,799 shares of the company’s stock, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders acquired 158,578 shares of company stock valued at $4,659,916 over the last three months. Insiders own 15.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in Radius Health in the third quarter worth approximately $110,000. Ameritas Investment Partners Inc. grew its position in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. grew its position in Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank bought a new stake in Radius Health in the second quarter worth approximately $211,000. Finally, Principal Financial Group Inc. grew its position in Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.